日本干眼症的药物治疗
本文概述了日本基于泪膜不稳定概念开发并上市的两种干眼治疗滴眼液——P2Y2拮抗剂Diquas和黏蛋白促分泌剂Mucosta——的疗效与特点,旨在加深对干眼症的理解。
要点
- 亚洲干眼学会认为泪膜不稳定是干眼主因,不同于美国的炎症理论。
- Diquas(P2Y2拮抗剂)和Mucosta(黏蛋白促分泌剂)基于泪膜不稳定概念在日本开发上市。
- Diquas已在韩国、泰国、越南等亚洲国家上市。
核心结论
- 基于泪膜不稳定概念开发的Diquas和Mucosta在日本被广泛用于干眼治疗。
研究设计与样本
- 本文为综述,总结两种滴眼液的疗效和特征。
主要发现
- Diquas和Mucosta在过去5年于日本开发上市并广泛处方。
- Diquas还在韩国、泰国、越南等亚洲国家上市。
临床怎么用
- 可依据泪膜不稳定机制选择Diquas或Mucosta治疗干眼。
局限性
- 干眼病因尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The etiology of dry eye has not been clarified. In the United States, the inflammation theory is supported as the main cause of dry eye, whereas the Asia Dry Eye Society has identified tear instability as the main cause. Based on this tear instability concept, the P2Y2 antagonist Diquas and the mucin secretagogue Mucosta were developed and launched in Japan over the last 5 years, and they have been widely prescribed to patients with dry eye. Moreover, Diquas has also been launched in other Asian countries, such as Korea, Thailand, and Vietnam. This report summarizes the efficacy and characteristics of these two eye drops to improve our understanding of dry eye.
引用
- Watanabe H. Medical Treatment for Dry Eye in Japan. Invest Ophthalmol Vis Sci. 2018. PMID: 30481815. doi:10.1167/iovs.18-24130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。